Pasar al contenido principal

ESTUDIO DEL CANNABIDIOL Y SU MECANISMO DE ACCION PARA EL TRATAMIENTO DEL SINDROME DE LEIGH

PID2021-125079OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vestibular CCK signaling drives motion sickness-like behavior in mice

  • Machuca Márquez, Pablo|||0000-0002-7980-3839
  • Sánchez Benito, Laura
  • Menardy, Fabien Louis Joseph|||0000-0002-8712-1344
  • Urpi, Andrea|||0000-0002-2437-7094
  • Girona, Mònica
  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
  • Appiah, Isabella|||0000-0002-4684-4992
  • Palmiter, Richard D.|||0000-0001-6587-0582
  • Sanz Iglesias, Elisenda|||0000-0002-7932-8556
  • Quintana Romero, Albert|||0000-0003-1674-7160
We live in an age where travel is paramount. However, one of the most disabling conditions inherent to traveling is motion sickness (MS). While studies have underscored the role of the vestibular system in the development of MS, the neuronal populations involved in motion-induced malaise remain largely unknown. Here, we describe the vestibular pathways eliciting MS responses and identify a key role for cholecystokinin (CCK)-expressing vestibular neurons. We reveal that a vestibulo-parabrachial (VN-PBN) CCKergic projection is sufficient to induce conditioned taste avoidance, likely through the activation of calcitonin gene-related peptide-expressing PBN neurons. Finally, we underscore the role of CCK-A receptor signaling as a druggable target to treat MS, providing insight on the neurobiological substrates of MS. Travel can induce motion sickness (MS) in susceptible individuals. MS is an evolutionary conserved mechanism caused by mismatches between motion-related sensory information and past visual and motion memory, triggering a malaise accompanied by hypolocomotion, hypothermia, hypophagia, and nausea. Vestibular nuclei (VN) are critical for the processing of movement input from the inner ear. Motion-induced activation of VN neurons recapitulates MS-related signs. However, the genetic identity of VN neurons mediating MS-related autonomic and aversive responses remains unknown. Here, we identify a central role of cholecystokinin (CCK)-expressing VN neurons in motion-induced malaise. Moreover, we show that CCK VN inputs onto the parabrachial nucleus activate Calca -expressing neurons and are sufficient to establish avoidance to novel food, which is prevented by CCK-A receptor antagonism. These observations provide greater insight into the neurobiological regulation of MS by identifying the neural substrates of MS and providing potential targets for treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
  • Luna Sánchez, Marta|||0000-0002-1315-3191
  • Gella, Alejandro|||0000-0002-3983-1392
  • Walt, Gunter van der|||0000-0001-5383-439X
  • Urpi, Andrea|||0000-0002-2437-7094
  • Royo, Maria|||0000-0003-3289-2624
  • Tena-Morraja, Paula
  • Appiah, Isabella|||0000-0002-4684-4992
  • Donato, Maria Helena de|||0009-0002-3602-3848
  • Menardy, Fabien Louis Joseph|||0000-0002-8712-1344
  • Bianchi, Patrizia|||0000-0003-3906-9104
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Rodríguez-Pascau, Laura
  • Vergara, Cristina
  • Gómez-Pallarès, Mercè|||0009-0007-7323-734X
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Martinell, Marc
  • Sanz Iglesias, Elisenda|||0000-0002-7932-8556
  • Jurado, Sandra
  • Soriano, Francesc Xavier
  • Pizcueta, Pilar
  • Quintana Romero, Albert|||0000-0003-1674-7160
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Streamlined Quantification of Microglial Morphology in Mouse Brains Using 3D Immunofluorescence Analysis

  • Donato, Maria Helena de|||0009-0002-3602-3848
  • Kouchaeknejad, Armin|||0009-0007-2769-3619
  • de Donato, Andreu
  • Walt, Gunter van der|||0000-0001-5383-439X
  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
Microglial cells are crucial patrolling immune cells in the brain and pivotal contributors to neuroinflammation during pathogenic or degenerative stress. Microglia exhibit a heterogeneous "dendrite-like" dense morphology that is subject to change depending on inflammatory status. Understanding the association between microglial morphology, reactivity, and neuropathology is key to informing treatment design in diverse neurodegenerative conditions from inherited encephalopathies to traumatic brain injuries. However, existing protocols for microglial morphology analyses lack standardization and are too complex and time-consuming for widescale adoption. Here, we describe a customized pipeline to quantitatively assess intricate microglial architecture in three dimensions under various conditions. This user-friendly workflow, comprising standard immunofluorescence staining, built-in functions of standard microscopy image analysis software, and custom Python scripts for data analysis, allows the measurement of important morphological parameters such as soma and dendrite volumes and branching levels for users of all skill levels. Overall, this protocol aims to simplify the quantification of the continuum of microglial pathogenic morphologies in biological and pharmacological studies, toward standardization of microglial morphometrics and improved inter-study comparability. Key features • Comparison of 3D microglial architecture between physiological and pathological conditions. • Quantitative assessment of critical microglial morphological features, including soma volume, dendrite volume, branch level, and filament length. • Simplified, semi-automated data export and analysis through simple Python scripts.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models

  • Puighermanal, Emma
  • Luna Sánchez, Marta
  • Gella, Alejandro
  • van der Walt, Gunter
  • Urpi, Andrea
  • Royo, María
  • Tena-Morraja, Paula
  • Appiah, Isabella
  • de Donato, María Helena
  • Menardy, Fabien
  • Bianchi, Patrizia
  • Esteve-Codina, Anna
  • Rodríguez-Pascau, Laura
  • Vergara, Cristina
  • Gómez-Pallarès, Mercè
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Martinell, Marc
  • Sanz, Elisenda
  • Jurado, Sandra
  • Soriano, Francesc Xavier
  • Pizcueta, Pilar
  • Quintana, Albert
Mutations in mitochondrial energy-producing genes lead to a heterogeneous group of untreatable disorders known as primary mitochondrial diseases (MD). Leigh syndrome (LS) is the most common pediatric MD and is characterized by progressive neuromuscular affectation and premature death. Here, we show that daily cannabidiol (CBD) administration significantly extends lifespan and ameliorates pathology in two LS mouse models, and improves cellular function in fibroblasts from LS patients. CBD delays motor decline and neurodegenerative signs, improves social deficits and breathing abnormalities, decreases thermally induced seizures, and improves neuropathology in affected brain regions. Mechanistically, we identify peroxisome proliferator-activated receptor gamma (PPARγ) as a key nuclear receptor mediating CBD's beneficial effects, while also providing proof of dysregulated PPARγ expression and activity as a common feature in both mouse neurons and fibroblasts from LS patients. Taken together, our results provide the first evidence for CBD as a potential treatment for LS., This work was supported by three MINECO Ramon y Cajal fellowships (RYC2020-029596-I; E.P., RYC2019-028501-I; E.S., and RyC-2012-11873; A.Q.), a Beatriu de Pinós fellowship from University and Research Grants Catalan Management Agency (#2017BP00132; E.P.) Marie Sklodowska-Curie Individual Fellowship (H2020-MSCA-IF-2014-658352; E.S., H2020-MSCA-IF-2020-101030783, M.L-S., H2020-MSCA-COFUND-2014-665919, A.G.), pre-doctoral fellowships (2018FI_B 00452 to AU, 2024 FI-1 00645 to GvdW). E.P received funds from MICINN (PID2021-125079OA-I00). E.S received funds from MICIU Proyectos I + D + i “Retos Investigacion” (RTI2018-101838-J-I00) and Ministerio de Ciencia e Innovación (MICINN) (PID2019-107633RB-I00 and PID2022-142544OB-I00). A.Q. is a recipient of an ICREA Academia award and received funds from the European Research Council (Starting grant NEUROMITO, ERC-2014-StG-638106), Grants SAF2014-57981P; SAF2017-88108-R, PID2020-114977RB-I00, RTC2019-006825-1, PDC2021-121883-I0, RED2022-134786-T, funded by MICIU/AEI /10.13039/5011000110330 and by MICIU/AEI /10.13039/501100011033 and Next GenerationEU/ PRTR, AGAUR (2017SGR-323, 2021SGR-720), Fundació TV3-La Marató (202030), and “la Caixa” Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400018., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Accelerating Leigh syndrome drug discovery through deep learning screening in brain organoids

  • Menacho, Carmen
  • Okawa, Satoshi
  • Álvarez-Merz, Iris
  • Wittich, Annika
  • Muñoz-Oreja, Mikel
  • Lisowski, Pawel
  • López Martín, Mario
  • Pentimalli, Tancredi Massimo
  • Zakin, Shiri
  • Thevandavakkam, Mathuravani
  • Jerred, Caleb
  • Lickfett, Selene
  • Petersilie, Laura
  • Rybak-Wolf, Agnieszka
  • Seibt, Annette
  • Herebian, Diran
  • Inak, Gizem
  • Brodesser, Susanne
  • Zaliani, Andrea
  • Mlody, Barbara
  • Donnelly, Justin
  • Woleben, Kasey
  • Soriano, Francesc Xavier
  • Fernández-Checa, José C.
  • Ventura, Natascia
  • Cambridge, Sidney
  • Mayatepek, Ertan
  • Spinazzola, Antonella
  • Schuelke, Markus
  • Rajewsky, Nikolaus
  • Rossi, Andrea
  • Peralvarez-Marin, Alex
  • Distelmaier, Felix
  • Perlstein, Ethan
  • Holt, Ian J.
  • Puighermanal, Emma
  • Pless, Ole
  • Rose, Christine R.
  • Del Sol, Antonio
  • Prigione, Alessandro
Leigh syndrome (Leigh) is an untreatable mitochondrial disorder characterized by lactic acidosis and basal ganglia and midbrain pathology, leading to psychomotor regression and early death. We previously uncovered impaired neuronal morphogenesis in Leigh cerebral organoids carrying SURF1 gene variants. Leveraging this phenotype, we here develop a deep learning algorithm tailored for cell type-specific drug repurposing screening. In parallel, we perform a survival drug screen in a yeast model of Leigh. The two approaches independently converge on azole compounds, two of which - talarozole and sertaconazole - rescue neuronal morphogenesis in Leigh neurons and lower lactate release and improve growth rate in Leigh midbrain organoids. Mechanistically, these compounds modulate the retinoic acid pathway and membrane-associate lipid metabolism. The findings highlight azoles as promising candidates for Leigh and demonstrate the potential of combining in silico screens with human brain organoids as new approach methodologies (NAMs) to advance the discovery of therapeutics addressing rare neurodevelopmental disorders., Open Access funding enabled and organized by Projekt DEAL. We thank Jens Schwamborn (Luxembourg University) and his group for providing their published MO datasets. We acknowledge support from the Deutsche Forschungsgemeinschaft (DFG) (PR1527/5-1, PR1527/6-1, PR1527/15-1, PR1527/14-1, and PR1527/13-1 to A.P.; RO5380/1-1 to A.R.; Ro2327/13-2 to C.R.R.; AL2956/1-1 to I.A-M.; VE366/12-1 to N.V.), the European Joint Programme on Rare Diseases (EJP RD) and Federal Ministry of Research, Technology and Space (BMFTR) (CureMILS #01GM2002A to A.P., #01GM2002B to O.P.), the Medical Faculty of Heinrich Heine University (FoKo grant to A.P. and S.C.), the European Commission’s Horizon Europe Programme (SIMPATHIC #101080249 to A.P. and M.S.), AFM-Téléthon (SildeMITO #28545 to A.P. and M.S.; GenT-Leigh #29044 to A.P.), the United Mitochondrial Disease Foundation (UMDF) and the Leigh Syndrome International Consortium (LSIC) (to A.P.), People Against Leigh syndrome (PALS) (to A.P.), the Foundation Maladies Rare and Association (AMMi) (to A.P.), the patient organizations Mitocon, Cure Mito, Cure ATP6, Mito Foundation, and MitoHelp (to A.P.), and the Eva Luise Köhler Foundation (to A.P. and M.S.), the Studienstiftung des deutschen Volkes (to S.L.), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGUAR) Generalitat de Catalunya through the Indústria del Coneixement LLAVOR program (grant 2024 LLAV 00069 to E.Pu.), National Science Center OPUS (#2017/27/B/NZ1/02401 to P.L.), and funds from MICINN (PID2021-125079OA-I00 to E.Pu.). A.Sp. and I.J.H. receive research support from the UK Medical Research Council (MR/X002365/1), Muscular Dystrophy UK (17GRO-PG24-0184-1), and the CHAMP Foundation. A.Sp. is the recipient of a Miriam Marks Senior Fellowship, Brain Research UK (202021-26) and receives funds from the Lily Foundation. I.J.H. is supported by grants from the Instituto de Salud Carlos III PI20/00096, the Spanish Ministry of Science, PID2023-151649NB-I00, and the Basque Government Department of Health (Osasun Saila, Eusko Jaurlaritzako) (grants 2021111070; 2022333050; 2018111043; 2018222031). M.M.O. was partially supported by the Ikerbasque, Basque Foundation for Science IKUR strategy, Neurodegenprot project. S.L. was supported by the Studienstiftung des deutschen Volkes. J.F-C acknowledges support from the MICINN (PID2022-142956OB-100 and PID2025-173094OB-I00), the National Cancer Institute PO1 CA281819-O1A1 from the NIH, and the CIBEREHD and the European Horizon´s research and Innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement #101095679). We are grateful to Anje Sporbert (Advanced Light Microscopy, MDC, Berlin) for help with the mitochondrial movement recordings and acknowledge the Center for Advanced Imaging (CAi) at Heinrich Heine University Düsseldorf for providing access to the PerkinElmer Operetta CLS (DFG grant # INST 208/760-1 FUGG) and Olympus FV3000 microscope., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS

  • Kouchaeknejad, Armin|||0009-0007-2769-3619
  • Walt, Gunter van der|||0000-0001-5383-439X
  • Donato, Maria Helena de|||0009-0002-3602-3848
  • Puighermanal Puigvert, Emma|||0000-0003-4271-9104
As central nervous system (CNS)-related disorders present an increasing cause of global morbidity, mortality, and high pressure on our healthcare system, there is an urgent need for new insights and treatment options. The endocannabinoid system (ECS) is a critical network of endogenous compounds, receptors, and enzymes that contribute to CNS development and regulation. Given its multifaceted involvement in neurobiology and its significance in various CNS disorders, the ECS as a whole is considered a promising therapeutic target. Despite significant advances in our understanding of the ECS's role in the CNS, its complex architecture and extensive crosstalk with other biological systems present challenges for research and clinical advancements. To bridge these knowledge gaps and unlock the full therapeutic potential of ECS interventions in CNS-related disorders, a plethora of molecular-genetic tools have been developed in recent years. Here, we review some of the most impactful tools for investigating the neurological aspects of the ECS. We first provide a brief introduction to the ECS components, including cannabinoid receptors, endocannabinoids, and metabolic enzymes, emphasizing their complexity. This is followed by an exploration of cutting-edge imaging tools and genetic models aimed at elucidating the roles of these principal ECS components. Special emphasis is placed on their relevance in the context of CNS and its associated disorders.